A Randomized, Double-Blinded, Placebo-Controlled, Dose-Finding, Adaptive Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Narcolepsy without Cataplexy (NT2)
TAK-360-2001
Phase 2 other active
Quick answer
A Randomized, Double-Blinded, Placebo-Controlled, Dose-Finding, Adaptive Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Narcolepsy without Cataplexy (NT2) for Narcolepsy without Cataplexy (NT2) is a Phase 2 program (other) at Takeda Pharmaceuticals International AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda Pharmaceuticals International AG
- Indication
- Narcolepsy without Cataplexy (NT2)
- Phase
- Phase 2
- Modality
- other
- Status
- active